![Stefan Weber](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stefan Weber
Director Ejecutivo en
NEWRON PHARMACEUTICALS S.P.A.
.
Perfil
Stefan Weber currently works at Newron Pharmaceuticals SpA, as Chief Executive Officer & Director from 2012, Newron Suisse SA, as Chairman & Chief Executive Officer, Hunter-Fleming Ltd., as Director, Newron Sweden AB, as General Manager & Director, and Newron Pharmaceuticals US, Inc., as Director.
Mr. Weber also formerly worked at Girindus AG i.L., as Chief Financial Officer from 2000 to 2001, Biofrontera AG, as Chief Financial Officer from 2001 to 2005, and Nikolaus & Claudius Lohmann, as Head-Finance from 1987 to 1999.
Mr. Weber received his graduate degree from the University of Hagen.
Cargos activos de Stefan Weber
| Empresas | Cargo | Inicio |
|---|---|---|
| NEWRON PHARMACEUTICALS S.P.A. | Director Ejecutivo | 15/05/2012 |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Director/Miembro de la Junta | - |
Newron Pharmaceuticals US, Inc.
 Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease. | Director/Miembro de la Junta | - |
Newron Suisse SA | Director Ejecutivo | - |
Hunter-Fleming Ltd.
 Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Stefan Weber.
| Empresas | Cargo | Fin |
|---|---|---|
| BIOFRONTERA AG | Director Financiero/CFO | 01/01/2005 |
| GIRINDUS AG IL | Director Financiero/CFO | 01/01/2001 |
Nikolaus & Claudius Lohmann | Director Financiero/CFO | 01/01/1999 |
Formación de Stefan Weber.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
20
Relaciones de 1er grado
9
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 9 |
|---|---|
Girindus AG i.L.
 Girindus AG i.L. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical products and chemical intermediate products | Health Technology |
Hunter-Fleming Ltd.
Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Biofrontera AG
 Biofrontera AG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops and distributes dermatological products | Health Technology |
Newron Pharmaceuticals SpA
 Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system | Health Technology |
Newron Sweden AB
Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders | Health Technology |
University of Hagen
 University of Hagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Newron Suisse SA | |
Newron Pharmaceuticals US, Inc.
Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease. | Commercial Services |
Nikolaus & Claudius Lohmann |
- Bolsa de valores
- Insiders
- Stefan Weber
